BlackRock
TRIB

BlackRock’s Trinity Biotech TRIB Stock Holding History

BlackRock’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-198
Closed -$1K – 5843
2022
Q3 		$1K Hold
198
– – ﹤0.01% 5771
2022
Q2 		$1K Buy
+198
New +$1.21K ﹤0.01% 5818
2019
Q1 		– Sell
-12,285
Closed -$141K – 5046
2018
Q4 		$141K Buy
+12,285
New +$190K ﹤0.01% 4290

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

BlackRock's TRIB Position: Q4 2022 in Review

BlackRock sold out of Trinity Biotech (TRIB) in Q4 2022, closing a stake of 198 shares — an estimated $1K sold.

BlackRock first reported a position in TRIB in Q4 2018 and held it in 3 quarters. The position peaked at $141K in Q4 2018. 20 funds tracked by Wall St. Rank hold TRIB as of Q4 2022.

  • BlackRock reported no remaining Trinity Biotech position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 198 Trinity Biotech shares in Q4 2022, an estimated $1K.
  • BlackRock first reported a position in Trinity Biotech in Q4 2018 and held it in 3 quarters.
  • BlackRock's Trinity Biotech position peaked at $141K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.